A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation

Prior treatment

• For participants with known concomitant second oncodriver for PDAC or for solid tumors.
• Prior anticancer therapy within 28 days or 5 half-lives

Other illness

• Other active malignancy within 3 years
• Symptomatic brain metastases, leptomeningeal disease, spinal cord compression, or primary brain tumor
• History of active clinically significant cardiovascular dysfunction
• With active infection (HIV, HBV, HCV, syphilis)
• Diagnosis of deep vein thrombosis or pulmonary embolism within 3 months
• Hypersensitivity to study drugs, or inability to swallow tablets or comply with study procedures.
• History of central nervous system (CNS)disease
• Presence of clinically significant interstitial lung disease, radiation pneumonitis, or immune-related pneumonia that requires treatment.

Other

• The presence of clinical or radiological evidence of intestinal obstruction.
• With uncontrollable or symptomatic pleural effusion, ascites, or pericardial effusion.

• Age ≥ 18 years
• Histologically or cytologically confirmed locally advanced or metastatic solid tumor and PDAC with RAS mutation or KRAS amplification
• At least one measurable lesion according to RECIST v1.1
• ECOG performance status 0 or 1
• Life expectancy \> 3 months
• Adequate organ function
• Willing to provide written informed consent
• Fertile participants must use effective contraception